biostudies-literatureUnknown11(9)Kassir NEtrolizumab is an IgG1-humanized monoclonal anti-β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately-to-severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibitors (HICKORY) or were TNF inhibitor naïve (HIBISCUS I/II, LAUREL, and GARDENIA). A total of eight exposure-response analyses were conducted for two clinical outcomes (remission and endoscopic improvement) at the end of induction for studies HIBISCUS I/II (combined) and HICKORY and at the end of maintenance for studies HICKORY and LAUREL. Trough concentration at week 4 (C_trough,wk4 ) of induction was selected as the exposure metric. Exposure-response (ER) modeling was conducted using logistic reCPT: pharmacometrics & systems pharmacology1234-1243https://www.ebi.ac.uk/biostudies/studies/S-EPMC9469693biostudies-literatureExposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis.PMC9469693Zhang WMoein AOh YSLangenhorst JKassir NRibbing JZhu RZhang RTang MTfalseExposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis.Etrolizumab is an IgG1-humanized monoclonal anti-β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately-to-severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibitors (HICKORY) or were TNF inhibitor naïve (HIBISCUS I/II, LAUREL, and GARDENIA). A total of eight exposure-response analyses were conducted for two clinical outcomes (remission and endoscopic improvement) at the end of induction for studies HIBISCUS I/II (combined) and HICKORY and at the end of maintenance for studies HICKORY and LAUREL. Trough concentration at week 4 (C_trough,wk4 ) of induction was selected as the exposure metric. Exposure-response (ER) modeling was conducted using logistic re2022-01-01T00:00:00Z2022 Sep2025-04-05T10:46:03.563Z2025-04-05T10:46:03.563ZS-EPMC94696933578954910.1002/psp4.12840